These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 19900861

  • 1. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
    Stepanski EJ, Houts AC, Schwartzberg LS, Walker MS, Reyes CM, Blakely J.
    Clin Lung Cancer; 2009 Nov; 10(6):426-32. PubMed ID: 19900861
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
    Boyer M, Horwood K, Pavlakis N, De Souza P, Millward M, Stein B, Johnston M, Abell F, Rischin D.
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):248-54. PubMed ID: 22898114
    [Abstract] [Full Text] [Related]

  • 3. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [Abstract] [Full Text] [Related]

  • 4. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D.
    J Clin Oncol; 2008 Feb 20; 26(6):863-9. PubMed ID: 18281658
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
    Gao H, Ding X, Wei D, Cheng P, Su X, Liu H, Aziz F, Wang D, Zhang T.
    Anticancer Drugs; 2011 Oct 20; 22(9):842-52. PubMed ID: 21808188
    [Abstract] [Full Text] [Related]

  • 6. Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience.
    Ailawadhi S, Derby L, Natarajan R, Fetterly G, Reid M, Ramnath N.
    Oncology; 2009 Oct 20; 76(2):85-90. PubMed ID: 19122466
    [Abstract] [Full Text] [Related]

  • 7. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA.
    J Clin Oncol; 2008 May 10; 26(14):2350-7. PubMed ID: 18467727
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Erlotinib in previously treated non-small-cell lung cancer.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group.
    N Engl J Med; 2005 Jul 14; 353(2):123-32. PubMed ID: 16014882
    [Abstract] [Full Text] [Related]

  • 12. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I, van der Hoek K, Malfair Taylor SC, Melosky B, Peacock S.
    Lung Cancer; 2012 Jun 14; 76(3):472-7. PubMed ID: 22226627
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
    Heigener DF, Wu YL, van Zandwijk N, Mali P, Horwood K, Reck M.
    Lung Cancer; 2011 Nov 14; 74(2):274-9. PubMed ID: 21439671
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR, Burris HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD.
    J Clin Oncol; 2011 Jun 20; 29(18):2582-9. PubMed ID: 21576636
    [Abstract] [Full Text] [Related]

  • 20. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N.
    Cancer Chemother Pharmacol; 2012 May 20; 69(5):1241-6. PubMed ID: 22278730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.